SCHEMBL4937359

SCHEMBL4937359

CN(Cc1ccc(N)cc1C(F)(F)F)C(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.48
GAA P10253 3/20 0.46
TSHR P16473 2/20 0.46
GLA P06280 1/20 0.46
POLB P06746 1/20 0.46
MAPT P10636 1/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35
IDO1 P14902 2/20 0.35
SLC6A2 P23975 5/20 0.33
SLC6A4 P31645 5/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
KIF11 P52732 1/20 0.33
PRKCI P41743 1/20 0.33
POLQ O75417 2/20 0.33
SLC6A3 Q01959 1/20 0.33
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
NOS2 P35228 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30401867 0.85 NR1H2 (0.51) NR1H2GAATSHRGLAPOLB
SCHEMBL374610 0.85 NR1H2 (0.51) NR1H2GAATSHRGLAPOLB
Hydrochloric Acid SCHEMBL16054675 0.83 NR1H2 (0.50) NR1H2GAATSHRGLAPOLB
SCHEMBL31053453 0.81 NR1H2 (0.51) NR1H2GAATSHRGLAPOLB
SCHEMBL1408378 0.79 PRKCI (0.57) NR1H2GAATSHRGLAPOLB
SCHEMBL20568125 0.78 NR1H2 (0.49) NR1H2GAATSHRGLAPOLB
SCHEMBL545297 0.78 NR1H2 (0.46) NR1H2GAATSHRGLAPOLB
SCHEMBL5423901 0.77 NR1H2 (0.48) NR1H2GAATSHRGLAPOLB
SCHEMBL22651953 0.76 SLC6A2 (0.48) POLBIDO1SLC6A2SLC6A4POLQ
SCHEMBL13991110 0.76 NR1H2 (0.47) NR1H2GAATSHRGLAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312192-A1 Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases BOLD GUIDO 2008-12-18 US disclosed
US-20080312192-A1 Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases BOLD GUIDO 2008-12-18 US disclosed
US-20080312192-A1 Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases BOLD GUIDO 2008-12-18 US disclosed
EP-1689376-A2 DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES Novartis AG (CH) 2006-08-16 EP disclosed
WO-2005051366-A2 DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312192-A1 Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases RET, PRKDC, PRKACA NR1H2 4001/4885GAA 1771/4885TSHR 2581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.